Trial record 1 of 13 for:    raptiva for chronic moderate to severe plaque psoriasis
Previous Study | Return to List | Next Study

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

This study has been completed.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00096928
First received: November 17, 2004
Last updated: March 11, 2011
Last verified: March 2011

November 17, 2004
March 11, 2011
March 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00096928 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

managed care organizations, community or physician practices, and academic centers in the United States

Psoriasis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1846
October 2009
Not Provided

Inclusion Criteria:

  • Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis and be a candidate for treatment with Raptiva
  • Are being treated with or initiating Raptiva therapy at the time of enrollment
  • Be able to provide written informed consent
  • Be willing and able to fully to participate for the duration of patient follow-up (5 years)

Exclusion Criterion:

  • Have previously received at least one dose of Raptiva and are not currently using or restarting treatment with Raptiva at the time of enrollment
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00096928
ACD3101g
Not Provided
Disclosures Group, Genentech, Inc.
Genentech
Not Provided
Study Director: Ivor Caro, M.D. Genentech
Genentech
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP